Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Obsessive-compulsive symptoms (OCS) are clinically important phenomena in schizophrenia patients. Lamotrigine has a modulating effect on glutamatergic neurotransmission relevant to pathophysiology of both schizophrenia and OCD. Efficacy and tolerability of lamotrigine in schizophrenia and schizoaffective patients with comorbid OCS were evaluated. In an 8-week, open-label trial, lamotrigine (25 mg/day for 1 week, 50 mg for 2 weeks, 100 mg for 2 weeks, 200 mg for 3 weeks) was added to ongoing psychotropic drug regimens in schizophrenia (N = 5) and schizoaffective disorder (N = 6) patients with clinically significant OCS [Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score > 16]. The Y-BOCS score for nine completers decreased significantly from baseline to week 8 (22.9 ± 6.1 vs 17.4 ± 3.6; t = 2.33, df = 1, P = 0.033). Five patients, all with schizoaffective disorder, were responders (≥35% decrease in Y-BOCS score). No significant changes were detected in schizophrenia symptom severity. Depressive symptoms, assessed with the Calgary Depression Rating Scale, improved significantly (6.4 ± 1.5 vs 4.0 ± 2.5; t = 3.19, df = 1, P = 0.013); this change positively correlated with OCS improvement (r = 0.69, P = 0.04). Lamotrigine was safe and well tolerated. Explicit evaluation of therapeutic efficacy of adjunctive lamotrigine in schizoaffective disorder patients with comorbid OCS merits further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Self-citationGlutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344
Response versus remission in obsessive-compulsive disorder
Simpson, H. B., Huppert, J. D., Petkova, E., Foa, E. B., & Liebowitz, M. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0214 · Cited by 241
Stabilization of Mood From Below Versus Above Baseline in Bipolar Disorder: A New Nomenclature
Ketter, T., & Calabrese, J. R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0210 · Cited by 161
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“Case reports of lamotrigine augmentation suggest benefit in OCD (Kumar & Khanna, 2000; Uzun, 2010); benefit has also been reported in schizoaffective patients with clinically significant OCD symptoms, in an open-label case series (Poyurovsky et al., 2010).”
BackgroundBarnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Anxiety comorbidity in schizophrenia
Braga, R. J., Reynolds, G. P., & Siris, S. G. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.07.030 · Cited by 182
Obsessive–compulsive disorder comorbidity: Clinical assessment and therapeutic implications
Pallanti, S., Grassi, G., Sarrecchia, E. D., Cantisani, A., & Pellegrini, M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00070 · Cited by 158
“Poyurovsky et al. (2010) conducted an 8 weeks open-label trial of lamotrigine augmentation in schizo-obsessive patients.”
Method
Metadata
- Authors
- Poyurovsky, M., Glick, I., & Koran, L.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-12-12
- Volume
- 24
- Issue
- 6
- Pages
- 861-866
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1984142485
- Cited by
- 65
- References
- 6
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. https://app.cochat.ai/papers/10.1177/0269881108099215
- The paper
- Poyurovsky, M., Glick, I., & Koran, L. (2010). Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. Journal of Psychopharmacology. https://doi.org/10.1177/0269881108099215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.